If that's possible - great. The IP would certainly take care of itself, and it's well known that enhanced glycosylation or modifying the sugars to include say more sialylation can alter kinetics. But what anotherbiotechguy mentioned, inserting a glycosylation signal sequence in the construct like what was done to epo to produce aranesp, might be an easier solution without the need for any sweeping change in GTCB's current production methods
Interesting, but perhaps prohibitive in terms of cost and paperwork. Each of those lines would require an IND of their own as they would be considered animal drugs, and then those containing your subsequent drug of interest would essentially be double transgenics.
Market Data 
Markets 
AI
